Skip to main content

Genetic Tests and FDA

FDA will convene a public meeting next week to hear from companies that make direct-to-consumer genetic tests, before it begins an overhaul of its regulations on genetic diagnostic testing, MIT's Technology Review says. FDA says doctors need help interpreting results from these tests, and that a third party should assess them before they are sold to the general public. "More than 2,000 genetic tests are now available through clinical laboratories," Technology Review's Emily Singer writes. FDA has made moves towards regulation of these tests in recent years, she adds, but the issue gained widespread notice in May when Pathway Genomics said it was going to sell its DTC genetic tests at Walgreens. (Walgreens called off the deal under FDA pressure, as our sister blog The Sample noted.) "The agency says it plans to take a risk-based approach, meaning that tests linked to major medical decisions will be more tightly regulated than those that might predict a minor increase in risk for disease," Singer says.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.